Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CORE JM7 is a medical cannabis flower product developed and distributed by DEMECAN. It is derived from the 'Jelly Mints' cultivar, which is an Indica-dominant hybrid strain created by crossing Animal Mints and Jelly Breath. The product is cultivated indoors in Germany or imported (e.g., from Canada) and is distributed unirradiated (unbestrahlt) to pharmacies. It is available in various THC:CBD ratios, such as 25:1, 28:1, and 31:1, containing high levels of tetrahydrocannabinol (THC) and minimal cannabidiol (CBD). The terpene profile is dominated by limonene, beta-caryophyllen, linalool, and alpha-pinene. It is prescribed for the treatment of chronic pain, depression, anxiety, stress, sleep disorders, and appetite loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CORE JM7.